company background image
LUMO logo

Lumos Pharma NasdaqGM:LUMO Stock Report

Last Price

US$4.34

Market Cap

US$37.5m

7D

0.3%

1Y

52.3%

Updated

13 Dec, 2024

Data

Company Financials +

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

LUMO Stock Overview

A clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. More details

LUMO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Lumos Pharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lumos Pharma
Historical stock prices
Current Share PriceUS$4.34
52 Week HighUS$4.58
52 Week LowUS$1.37
Beta0.31
1 Month Change0.93%
3 Month Change10.43%
1 Year Change52.28%
3 Year Change-40.79%
5 Year Changen/a
Change since IPO-50.46%

Recent News & Updates

Recent updates

We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

May 23
We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

Aug 25
We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Mar 13
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Lumos Pharma announces new buyback program

Aug 16

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Mar 22
Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Nov 04
Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Dec 09
What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Nov 17

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

Shareholder Returns

LUMOUS BiotechsUS Market
7D0.3%2.1%2.8%
1Y52.3%-3.8%24.5%

Return vs Industry: LUMO exceeded the US Biotechs industry which returned 6% over the past year.

Return vs Market: LUMO exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is LUMO's price volatile compared to industry and market?
LUMO volatility
LUMO Average Weekly Movement7.2%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.1%

Stable Share Price: LUMO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: LUMO's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a30Rick Hawkinslumos-pharma.com

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease.

Lumos Pharma, Inc. Fundamentals Summary

How do Lumos Pharma's earnings and revenue compare to its market cap?
LUMO fundamental statistics
Market capUS$37.54m
Earnings (TTM)-US$34.92m
Revenue (TTM)US$2.21m

17.0x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LUMO income statement (TTM)
RevenueUS$2.21m
Cost of RevenueUS$0
Gross ProfitUS$2.21m
Other ExpensesUS$37.12m
Earnings-US$34.92m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.04
Gross Margin100.00%
Net Profit Margin-1,583.49%
Debt/Equity Ratio0%

How did LUMO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/13 20:39
End of Day Share Price 2024/12/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lumos Pharma, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Eun Kyung YangJefferies LLC
Elemer PirosRoth MKM